Comprehensive Physiology Wiley Online Library
For Librarians For Authors Editors About

Tensions in Taxonomies: Current Understanding and Future Directions in the Pathobiologic Basis and Treatment of Group 1 and Group 3 Pulmonary Hypertension

Sue Gu, Khushboo Goel, Lindsay M. Forbes, Vitaly O. Kheyfets, Yen‐rei A. Yu, Rubin M. Tuder, Kurt R. Stenmark

10.1002/cphy.c220010

Source: Volume 13, Issue 1, January 2023

Published online: January 2023

Full Article on Wiley Online Library



Abstract

In the over 100 years since the recognition of pulmonary hypertension (PH), immense progress and significant achievements have been made with regard to understanding the pathophysiology of the disease and its treatment. These advances have been mostly in idiopathic pulmonary arterial hypertension (IPAH), which was classified as Group 1 Pulmonary Hypertension (PH) at the Second World Symposia on PH in 1998. However, the pathobiology of PH due to chronic lung disease, classified as Group 3 PH, remains poorly understood and its treatments thus remain limited. We review the history of the classification of the five groups of PH and aim to provide a state‐of‐the‐art review of the understanding of the pathogenesis of Group 1 PH and Group 3 PH including insights gained from novel high‐throughput omics technologies that have revealed heterogeneities within these categories as well as similarities between them. Leveraging the substantial gains made in understanding the genomics, epigenomics, proteomics, and metabolomics of PAH to understand the full spectrum of the complex, heterogeneous disease of PH is needed. Multimodal omics data as well as supervised and unbiased machine learning approaches after careful consideration of the powerful advantages as well as of the limitations and pitfalls of these technologies could lead to earlier diagnosis, more precise risk stratification, better predictions of disease response, new sub‐phenotype groupings within types of PH, and identification of shared pathways between PAH and other types of PH that could lead to new treatment targets. © 2023 American Physiological Society. Compr Physiol 13:4295‐4319, 2023.

Figure 1. Figure 1. Survival in Group 1 and Group 3 PH. Reused, with permission, from Prins KW, et al., 2018 137, American Thoracic Society.
Figure 2. Figure 2. Pathogenic concepts of pulmonary arterial hypertension: Differences and similarities with cancer. FGF, fibroblast growth factor; PDGF, platelet‐derived growth factor; EGF, epidermal growth factor; BMPR2, bone morphogenetic protein receptor 2; ECM, extracellular matrix; ET‐1, endothelin‐1; 5‐HT, serotonin; NO, nitric oxide; PGI2, prostacyclin; Th, T‐helper cell; Treg, regulatory T‐cell; VEGF, vascular endothelial growth factor. Reused, with permission, from Guignabert C, et al., 2013 66, European Respiratory Society.
Figure 3. Figure 3. Inflammatory components in plexiform type lesions of PAH. Inflammatory cells are highlighted by the anti‐CD45 immunostaining (arrowheads) (A), B‐cell marker (UL‐26) (B), T‐cell marker (UCHSC) (C), and macrophage marker (CD68) (D and E) (arrowheads). Note infiltration of the outer portion of the plexogenic vessel (D) and vessel obliterated by concentric proliferation (E) by macrophages (immunoperoxidase, A‐C, E 500X; D: 200x). I‐Vascular lumen. Reused, with permission, from Tuder RM, et al., 1994 198, from Elsevier.
Figure 4. Figure 4. Inflammatory and fibrotic processes in usual interstitial pneumonia with marked pulmonary vascular remodeling. (A) Low magnification of subpleural region showing marked subpleural fibrosis (arrow), extending irregularly toward central regions of the lung with conglomerates of lymphoid cells (arrowhead) (Hematoxilin and Eosin). (B) Marked perivascular (arrows) and airway (yellow arrow) fibrosis and inflammation, forming a continuous process along the bronchovascular and parencymal structures. The pulmonary arteries show intima thickening, with significant obliteration of the vascular lumina (Pentachrome). (C) Exudative fibroblastic focus (arrowhead) next to small pulmonary artery (arrowhead), accompanied by scattered inflammatory cells (Pentachrome). (D) Active bridging fibrosis along alveolar and bronchovascular (yellow arrow) associated with exudative process (arrow) and inflammation (arrowhead). Note the marked obliteration of an adjacent pulmonary artery (long arrow) (Pentachrome). (E) Active inflammation and interstitial fibrosis in the advancing edge of usual interstitial pneumonia (yellow arrow) (Hematoxilin and eosin). (F) Marked media and intima thickening in muscular artery (arrows) in a region not immediately affected by UIP (arrows) (Hematoxilin and eosin).
Figure 5. Figure 5. Survival analysis of based on a panel of plasma proteins and REVEAL score in an observational cohort of idiopathic and heritable PAH patients. Kaplan‐Meier survival estimates in patients with different panel scores, in all patients with idiopathic pulmonary arterial hypertension from (A) cohorts 1 and 2 and (B) cohort 4. ROC analysis of Cox models before and after addition of the prognostic protein panel to the established equation, in all patients with idiopathic pulmonary arterial hypertension from (C) cohorts 1 and 2 and (D) cohort 4. ROC, receiver operating characteristic; AUC, area under the curve. Reused, with permission, from Rhodes CJ, et al., 2017 152/Elsevier/CC BY 4.0.
Figure 6. Figure 6. Metabolic pathways and potential therapeutic interventions in PH. CHC, a‐cyano‐4‐hydroxycinnamic acid; DCA, dichloroacetate; PDK, pyruvate dehydrogenase kinase. Reused, with permission, from D'Alessandro A, et al., 38/with permission of Mary Ann Liebert.


Figure 1. Survival in Group 1 and Group 3 PH. Reused, with permission, from Prins KW, et al., 2018 137, American Thoracic Society.


Figure 2. Pathogenic concepts of pulmonary arterial hypertension: Differences and similarities with cancer. FGF, fibroblast growth factor; PDGF, platelet‐derived growth factor; EGF, epidermal growth factor; BMPR2, bone morphogenetic protein receptor 2; ECM, extracellular matrix; ET‐1, endothelin‐1; 5‐HT, serotonin; NO, nitric oxide; PGI2, prostacyclin; Th, T‐helper cell; Treg, regulatory T‐cell; VEGF, vascular endothelial growth factor. Reused, with permission, from Guignabert C, et al., 2013 66, European Respiratory Society.


Figure 3. Inflammatory components in plexiform type lesions of PAH. Inflammatory cells are highlighted by the anti‐CD45 immunostaining (arrowheads) (A), B‐cell marker (UL‐26) (B), T‐cell marker (UCHSC) (C), and macrophage marker (CD68) (D and E) (arrowheads). Note infiltration of the outer portion of the plexogenic vessel (D) and vessel obliterated by concentric proliferation (E) by macrophages (immunoperoxidase, A‐C, E 500X; D: 200x). I‐Vascular lumen. Reused, with permission, from Tuder RM, et al., 1994 198, from Elsevier.


Figure 4. Inflammatory and fibrotic processes in usual interstitial pneumonia with marked pulmonary vascular remodeling. (A) Low magnification of subpleural region showing marked subpleural fibrosis (arrow), extending irregularly toward central regions of the lung with conglomerates of lymphoid cells (arrowhead) (Hematoxilin and Eosin). (B) Marked perivascular (arrows) and airway (yellow arrow) fibrosis and inflammation, forming a continuous process along the bronchovascular and parencymal structures. The pulmonary arteries show intima thickening, with significant obliteration of the vascular lumina (Pentachrome). (C) Exudative fibroblastic focus (arrowhead) next to small pulmonary artery (arrowhead), accompanied by scattered inflammatory cells (Pentachrome). (D) Active bridging fibrosis along alveolar and bronchovascular (yellow arrow) associated with exudative process (arrow) and inflammation (arrowhead). Note the marked obliteration of an adjacent pulmonary artery (long arrow) (Pentachrome). (E) Active inflammation and interstitial fibrosis in the advancing edge of usual interstitial pneumonia (yellow arrow) (Hematoxilin and eosin). (F) Marked media and intima thickening in muscular artery (arrows) in a region not immediately affected by UIP (arrows) (Hematoxilin and eosin).


Figure 5. Survival analysis of based on a panel of plasma proteins and REVEAL score in an observational cohort of idiopathic and heritable PAH patients. Kaplan‐Meier survival estimates in patients with different panel scores, in all patients with idiopathic pulmonary arterial hypertension from (A) cohorts 1 and 2 and (B) cohort 4. ROC analysis of Cox models before and after addition of the prognostic protein panel to the established equation, in all patients with idiopathic pulmonary arterial hypertension from (C) cohorts 1 and 2 and (D) cohort 4. ROC, receiver operating characteristic; AUC, area under the curve. Reused, with permission, from Rhodes CJ, et al., 2017 152/Elsevier/CC BY 4.0.


Figure 6. Metabolic pathways and potential therapeutic interventions in PH. CHC, a‐cyano‐4‐hydroxycinnamic acid; DCA, dichloroacetate; PDK, pyruvate dehydrogenase kinase. Reused, with permission, from D'Alessandro A, et al., 38/with permission of Mary Ann Liebert.
References
 1.Abdul‐Salam VB, Wharton J, Cupitt J, Berryman M, Edwards RJ, Wilkins MR. Proteomic analysis of lung tissues from patients with pulmonary arterial hypertension. Circulation 122: 2058‐2067, 2010.
 2.Abe K, Toba M, Alzoubi A, Ito M, Fagan KA, Cool CD, Voelkel NF, McMurtry IF, Oka M. Formation of plexiform lesions in experimental severe pulmonary arterial hypertension. Circulation 121: 2747‐2754, 2010.
 3.Abid S, Marcos E, Parpaleix A, Amsellem V, Breau M, Houssaini A, Vienney N, Lefevre M, Derumeaux G, Evans S, Hubeau C, Delcroix M, Quarck R, Adnot S, Lipskaia L. CCR2/CCR5‐mediated macrophage‐smooth muscle cell crosstalk in pulmonary hypertension. Eur Respir J 54: 1802308, 2019.
 4.Acharya AP, Tang Y, Bertero T, Tai YY, Harvey LD, Woodcock CC, Sun W, Pineda R, Mitash N, Konigshoff M, Little SR, Chan SY. Simultaneous pharmacologic inhibition of yes‐associated protein 1 and glutaminase 1 via inhaled poly(lactic‐co‐glycolic) acid‐encapsulated microparticles improves pulmonary hypertension. J Am Heart Assoc 10: e019091, 2021.
 5.Aldred MA, Comhair SA, Varella‐Garcia M, Asosingh K, Xu W, Noon GP, Thistlethwaite PA, Tuder RM, Erzurum SC, Geraci MW, Coldren CD. Somatic chromosome abnormalities in the lungs of patients with pulmonary arterial hypertension. Am J Respir Crit Care Med 182: 1153‐1160, 2010.
 6.Archer SL, Marsboom G, Kim GH, Zhang HJ, Toth PT, Svensson EC, Dyck JR, Gomberg‐Maitland M, Thebaud B, Husain AN, Cipriani N, Rehman J. Epigenetic attenuation of mitochondrial superoxide dismutase 2 in pulmonary arterial hypertension: A basis for excessive cell proliferation and a new therapeutic target. Circulation 121: 2661‐2671, 2010.
 7.Baig MH, Ahmad K, Roy S, Ashraf JM, Adil M, Siddiqui MH, Khan S, Kamal MA, Provaznik I, Choi I. Computer aided drug design: Success and limitations. Curr Pharm Des 22: 572‐581, 2016.
 8.Bailey DM, Dehnert C, Luks AM, Menold E, Castell C, Schendler G, Faoro V, Gutowski M, Evans KA, Taudorf S, James PE, McEneny J, Young IS, Swenson ER, Mairbäurl H, Bärtsch P, Berger MM. High‐altitude pulmonary hypertension is associated with a free radical‐mediated reduction in pulmonary nitric oxide bioavailability. J Physiol 588: 4837‐4847, 2010.
 9.Barberà JA, Blanco I. Pulmonary hypertension in patients with chronic obstructive pulmonary disease. Drugs 69: 1153‐1171, 2009.
 10.Barbera JA, Peinado VI, Santos S, Ramirez J, Roca J, Rodriguez‐Roisin R. Reduced expression of endothelial nitric oxide synthase in pulmonary arteries of smokers. Am J Respir Crit Care Med 164: 709‐713, 2001.
 11.Barry PJ, Mall MA, Alvarez A, Colombo C, de Winter‐de Groot KM, Fajac I, KA MB, EF MK, Ramsey BW, Sutharsan S, Taylor‐Cousar JL, Tullis E, Ahluwalia N, Jun LS, Moskowitz SM, Prieto‐Centurion V, Tian S, Waltz D, Xuan F, Zhang Y, Rowe SM, Polineni D, Group VXS. Triple therapy for cystic fibrosis Phe508del‐gating and ‐residual function genotypes. N Engl J Med 385: 815‐825, 2021.
 12.Bauer Y, de Bernard S, Hickey P, Ballard K, Cruz J, Cornelisse P, Chadha‐Boreham H, Distler O, Rosenberg D, Doelberg M, Roux S, Nayler O, Lawrie A. Identifying early pulmonary arterial hypertension biomarkers in systemic sclerosis: Machine learning on proteomics from the DETECT cohort. Eur Respir J 57, 2021.
 13.Benza RL, Gomberg‐Maitland M, Elliott CG, Farber HW, Foreman AJ, Frost AE, McGoon MD, Pasta DJ, Selej M, Burger CD, Frantz RP. Predicting survival in patients with pulmonary arterial hypertension: The REVEAL risk score calculator 2.0 and comparison with ESC/ERS‐based risk assessment strategies. Chest 156: 323‐337, 2019.
 14.Benza RL, Miller DP, Gomberg‐Maitland M, Frantz RP, Foreman AJ, Coffey CS, Frost A, Barst RJ, Badesch DB, Elliott CG, Liou TG, McGoon MD. Predicting survival in pulmonary arterial hypertension: Insights from the Registry to Evaluate Early and Long‐Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 122: 164‐172, 2010.
 15.Berger MM, Dehnert C, Bailey DM, Luks AM, Menold E, Castell C, Schendler G, Faoro V, Mairbäurl H, Bärtsch P, Swenson ER. Transpulmonary plasma ET‐1 and nitrite differences in high altitude pulmonary hypertension. High Alt Med Biol 10: 17‐24, 2009.
 16.Bertero T, Lu Y, Annis S, Hale A, Bhat B, Saggar R, Saggar R, Wallace WD, Ross DJ, Vargas SO, Graham BB, Kumar R, Black SM, Fratz S, Fineman JR, West JD, Haley KJ, Waxman AB, Chau BN, Cottrill KA, Chan SY. Systems‐level regulation of microRNA networks by miR‐130/301 promotes pulmonary hypertension. J Clin Invest 124: 3514‐3528, 2014.
 17.Blanco I, Santos S, Gea J, Guell R, Torres F, Gimeno‐Santos E, Rodriguez DA, Vilaro J, Gomez B, Roca J, Barbera JA. Sildenafil to improve respiratory rehabilitation outcomes in COPD: A controlled trial. Eur Respir J 42: 982‐992, 2013.
 18.Blanco I, Tura‐Ceide O, Peinado VI, Barbera JA. Updated perspectives on pulmonary hypertension in COPD. Int J Chron Obstruct Pulmon Dis 15: 1315‐1324, 2020.
 19.Borck PC, Guo LW, Plutzky J. BET epigenetic reader proteins in cardiovascular transcriptional programs. Circ Res 126: 1190‐1208, 2020.
 20.Brito J, Siques P, López R, Romero R, León‐Velarde F, Flores K, Lüneburg N, Hannemann J, Böger RH. Long‐term intermittent work at high altitude: Right heart functional and morphological status and associated cardiometabolic factors. Front Physiol 9: 248, 2018.
 21.Brito J, Siques P, Pena E. Long‐term chronic intermittent hypoxia: A particular form of chronic high‐altitude pulmonary hypertension. Pulm Circ 10: 5‐12, 2020.
 22.Brittain EL, Hemnes AR. Introduction to review series on pulmonary vascular disease and right ventricular heart failure. Circ Res 130: 1362‐1364, 2022.
 23.Bunel V, Guyard A, Dauriat G, Danel C, Montani D, Gauvain C, Thabut G, Humbert M, Castier Y, Dorfmüller P, Mal H. Pulmonary arterial histologic lesions in patients with COPD with severe pulmonary hypertension. Chest 156: 33‐44, 2019.
 24.Carlsen J, Henriksen HH, Marin de Mas I, Johansson PI. An explorative metabolomic analysis of the endothelium in pulmonary hypertension. Sci Rep 12: 13284, 2022.
 25.Cavasin MA, Stenmark KR, McKinsey TA. Emerging roles for histone deacetylases in pulmonary hypertension and right ventricular remodeling (2013 Grover Conference series). Pulm Circ 5: 63‐72, 2015.
 26.Chan HCS, Shan H, Dahoun T, Vogel H, Yuan S. Advancing drug discovery via artificial intelligence. Trends Pharmacol Sci 40: 592‐604, 2019.
 27.Chaouat A, Bugnet AS, Kadaoui N, Schott R, Enache I, Ducoloné A, Ehrhart M, Kessler R, Weitzenblum E. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 172: 189‐194, 2005.
 28.Chaouat A, Naeije R, Weitzenblum E. Pulmonary hypertension in COPD. Eur Respir J 32: 1371‐1385, 2008.
 29.Chatterjee K, Tarawneh AR, Alam S. Out of proportion pulmonary hypertension in obstructive lung diseases. Curr Opin Pulm Med 24: 161‐172, 2018.
 30.Chen NY, Collum SD, Luo F, Weng T, Le TT AMH, Philip K, Molina JG, Garcia‐Morales LJ, Cao Y, Ko TC, Amione‐Guerra J, Al‐Jabbari O, Bunge RR, Youker K, Bruckner BA, Hamid R, Davies J, Sinha N, Karmouty‐Quintana H. Macrophage bone morphogenic protein receptor 2 depletion in idiopathic pulmonary fibrosis and Group III pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 311: L238‐L254, 2016.
 31.Collum SD, Amione‐Guerra J, Cruz‐Solbes AS, DiFrancesco A, Hernandez AM, Hanmandlu A, Youker K, Guha A, Karmouty‐Quintana H. Pulmonary hypertension associated with idiopathic pulmonary fibrosis: Current and future perspectives. Can Respir J 2017: 1430350, 2017.
 32.Consortium TIP, Lane KB, Machado RD, Pauciulo MW, Thompson JR, Philips JA III, Loyd JE, Nichols WC, Trembath RC. Heterozygous germline mutations in BMPR2 encoding a TGF‐B receptor cause familiar pulmonary hypertension. Nat Genet 26: 81‐84, 2000.
 33.Cool CD, Groshong SD, Rai PR, Henson PM, Stewart JS, Brown KK. Fibroblast foci are not discrete sites of lung injury or repair: The fibroblast reticulum. Am J Respir Crit Care Med 174: 654‐658, 2006.
 34.Cool CD, Kuebler WM, Bogaard HJ, Spiekerkoetter E, Nicolls MR, Voelkel NF. The hallmarks of severe pulmonary arterial hypertension: The cancer hypothesis ‐ ten years later. Am J Physiol Lung Cell Mol Physiol 318 (6): L1115‐L1130, 2020.
 35.Cool CD, Stewart JS, Werahera P, Miller GJ, Williams RL, Voelkel NF, Tuder RM. Three‐dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell specific markers: Evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth. Am J Pathol 155: 411‐419, 1999.
 36.Corte TJ, Keir GJ, Dimopoulos K, Howard L, Corris PA, Parfitt L, Foley C, Yanez‐Lopez M, Babalis D, Marino P, Maher TM, Renzoni EA, Spencer L, Elliot CA, Birring SS, O'Reilly K, Gatzoulis MA, Wells AU, Wort SJ, Group BS. Bosentan in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia. Am J Respir Crit Care Med 190: 208‐217, 2014.
 37.Cosgrove GP, Brown KK, Schiemann WP, Serls AE, Parr JE, Geraci MW, Schwarz MI, Cool CD, Worthen GS. Pigment epithelium‐derived factor in idiopathic pulmonary fibrosis: A role in aberrant angiogenesis. Am J Respir Crit Care Med 170: 242‐251, 2004.
 38.D'Alessandro A, El Kasmi KC, Plecita‐Hlavata L, Jezek P, Li M, Zhang H, Gupte SA, Stenmark KR. Hallmarks of pulmonary hypertension: Mesenchymal and inflammatory cell metabolic reprogramming. Antioxid Redox Signal 28: 230‐250, 2018.
 39.Das M, Dempsey EC, Reeves JT, Stenmark KR. Selective expansion of fibroblast subpopulations from pulmonary artery adventitia in response to hypoxia. Am J Physiol Lung Cell Mol Physiol 282: L976‐L986, 2002.
 40.Davie NJ, Crossno JT Jr, Frid MG, Hofmeister SE, Reeves JT, Hyde DM, Carpenter TC, Brunetti JA, McNiece IK, Stenmark KR. Hypoxia‐induced pulmonary artery adventitial remodeling and neovascularization: Contribution of progenitor cells. Am J Physiol Lung Cell Mol Physiol 286: L668‐L678, 2004.
 41.De Cunto G, Cardini S, Cirino G, Geppetti P, Lungarella G, Lucattelli M. Pulmonary hypertension in smoking mice over‐expressing protease‐activated receptor‐2. Eur Respir J 37: 823‐834, 2011.
 42.Deng Z, Morse JH, Slager SL, Cuervo N, Moore KJ, Venetos G, Kalachikov S, Cayanis E, Fischer SG, Barst RJ, Hodge SE, Knowles JA. Familial primary pulmonary hypertension (gene PPH1) Is caused by mutations in the bone morphogenetic protein receptor‐II gene. Am J Hum Genet 67: 737‐744, 2000.
 43.Dieffenbach PB, Haeger CM, Coronata AMF, Choi KM, Varelas X, Tschumperlin DJ, Fredenburgh LE. Arterial stiffness induces remodeling phenotypes in pulmonary artery smooth muscle cells via YAP/TAZ‐mediated repression of cyclooxygenase‐2. Am J Physiol Lung Cell Mol Physiol 313: L628‐L647, 2017.
 44.Dieffenbach PB, Mallarino Haeger C, Rehman R, Corcoran AM, Coronata AMF, Vellarikkal SK, Chrobak I, Waxman AB, Vitali SH, Sholl LM, Padera RF, Lagares D, Polverino F, Owen CA, Fredenburgh LE. A novel protective role for matrix metalloproteinase‐8 in the pulmonary vasculature. Am J Respir Crit Care Med 204: 1433‐1451, 2021.
 45.Dierick F, Solinc J, Bignard J, Soubrier F, Nadaud S. Progenitor/stem cells in vascular remodeling during pulmonary arterial hypertension. Cell 10: 1338, 2021.
 46.Dunmore BJ, Jones RJ, Toshner MR, Upton PD, Morrell NW. Approaches to treat pulmonary arterial hypertension by targeting BMPR2: From cell membrane to nucleus. Cardiovasc Res 117: 2309‐2325, 2021.
 47.Errington N, Iremonger J, Pickworth JA, Kariotis S, Rhodes CJ, Rothman AM, Condliffe R, Elliot CA, Kiely DG, Howard LS, Wharton J, Thompson AAR, Morrell NW, Wilkins MR, Wang D, Lawrie A. A diagnostic miRNA signature for pulmonary arterial hypertension using a consensus machine learning approach. EBioMedicine 69: 103444, 2021.
 48.Farkas L, Farkas D, Ask K, Moller A, Gauldie J, Margetts P, Inman M, Kolb M. VEGF ameliorates pulmonary hypertension through inhibition of endothelial apoptosis in experimental lung fibrosis in rats. J Clin Invest 119: 1298‐1311, 2009.
 49.Farkas L, Gauldie J, Voelkel NF, Kolb M. Pulmonary hypertension and idiopathic pulmonary fibrosis: A tale of angiogenesis, apoptosis, and growth factors. Am J Respir Cell Mol Biol 45: 1‐15, 2011.
 50.Fauvel C, Raitière O, Belkacem NS, Dominique S, Artaud‐Macari E, Viacroze C, Schleifer D, Bauer F. Prognostic importance of Kidney, Heart and Interstitial lung diseases (KHI triad) in PH: A machine learning study. Arch Cardiovasc Dis 113: 630‐641, 2020.
 51.Federici C, Drake KM, Rigelsky CM, McNelly LN, Meade SL, Comhair SA, Erzurum SC, Aldred MA. Increased mutagen sensitivity and DNA damage in pulmonary arterial hypertension. Am J Respir Crit Care Med 192: 219‐228, 2015.
 52.Fessel JP, Hamid R, Wittmann BM, Robinson LJ, Blackwell T, Tada Y, Tanabe N, Tatsumi K, Hemnes AR, West JD. Metabolomic analysis of bone morphogenetic protein receptor type 2 mutations in human pulmonary endothelium reveals widespread metabolic reprogramming. Pulm Circ 2: 201‐213, 2012.
 53.Firth AL, Remillard CV, Platoshyn O, Fantozzi I, Ko EA, Yuan JX. Functional ion channels in human pulmonary artery smooth muscle cells: Voltage‐dependent cation channels. Pulm Circ 1: 48‐71, 2011.
 54.Florentin J, Coppin E, Vasamsetti SB, Zhao J, Tai YY, Tang Y, Zhang Y, Watson A, Sembrat J, Rojas M, Vargas SO, Chan SY, Dutta P. Inflammatory macrophage expansion in pulmonary hypertension depends upon mobilization of blood‐borne monocytes. J Immunol 200: 3612‐3625, 2018.
 55.Frid MG, Brunetti JA, Burke DL, Carpenter TC, Davie NJ, Reeves JT, Roedersheimer MT, van Rooijen N, Stenmark KR. Hypoxia‐induced pulmonary vascular remodeling requires recruitment of circulating mesenchymal precursors of a monocyte/macrophage lineage. Am J Pathol 168: 659‐669, 2006.
 56.Frid MG, Dempsey EC, Durmowicz AG, Stenmark KR. Smooth muscle cell heterogeneity in pulmonary and systemic vessels. Importance in vascular disease. Arterioscler Thromb Vasc Biol 17: 1203‐1209, 1997.
 57.Frid MG, McKoen BA, Thurman JM, Maron BA, Li M, Zhang H, Kumar S, Sullivan T, Laskowsky J, Fini MA, Hu S, Tuder RM, Gandjeva A, Wilkins MR, Rhodes CJ, Ghataorphe P, Leopold JA, Wang R‐S, Holers VM, Stenmark KR. Immunoglobulin‐driven complement activation regulates pro‐inflammatory remodeling in pulmonary hypertension. Am J Respir Crit Care Med 201 (2): 224‐239, 2020.
 58.Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, Williams PG, Souza R. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 53: 1801913, 2019.
 59.Ghigna M‐R, Dorfmüller P. Pulmonary vascular disease and pulmonary hypertension. Diagn Histopathol 25: 304‐312, 2019.
 60.Ghigna MR, Mooi WJ, Grunberg K. Pulmonary hypertensive vasculopathy in parenchymal lung diseases and/or hypoxia: Number 1 in the Series “Pathology for the clinician” Edited by Peter Dorfmuller and Alberto Cavazza. Eur Respir Rev 26: 170003, 2017.
 61.Gou Q, Shi R, Zhang X, Meng Q, Li X, Rong X, Gawa Z, Zhuoma N, Chen X. The prevalence and risk factors of high‐altitude pulmonary hypertension among native Tibetans in Sichuan Province China. High Alt Med Biol 21: 327‐335, 2020.
 62.Goudie AR, Lipworth BJ, Hopkinson PJ, Wei L, Struthers AD. Tadalafil in patients with chronic obstructive pulmonary disease: A randomised, double‐blind, parallel‐group, placebo‐controlled trial. Lancet Respir Med 2: 293‐300, 2014.
 63.Graf S, Haimel M, Bleda M, Hadinnapola C, Southgate L, Li W, Hodgson J, Liu B, Salmon RM, Southwood M, Machado RD, Martin JM, Treacy CM, Yates K, Daugherty LC, Shamardina O, Whitehorn D, Holden S, Aldred M, Bogaard HJ, Church C, Coghlan G, Condliffe R, Corris PA, Danesino C, Eyries M, Gall H, Ghio S, Ghofrani HA, Gibbs JSR, Girerd B, Houweling AC, Howard L, Humbert M, Kiely DG, Kovacs G, MacKenzie Ross RV, Moledina S, Montani D, Newnham M, Olschewski A, Olschewski H, Peacock AJ, Pepke‐Zaba J, Prokopenko I, Rhodes CJ, Scelsi L, Seeger W, Soubrier F, Stein DF, Suntharalingam J, Swietlik EM, Toshner MR, van Heel DA, Vonk Noordegraaf A, Waisfisz Q, Wharton J, Wort SJ, Ouwehand WH, Soranzo N, Lawrie A, Upton PD, Wilkins MR, Trembath RC, Morrell NW. Identification of rare sequence variation underlying heritable pulmonary arterial hypertension. Nat Commun 9: 1416, 2018.
 64.Gredic M, Blanco I, Kovacs G, Helyes Z, Ferdinandy P, Olschewski H, Barbera JA, Weissmann N. Pulmonary hypertension in chronic obstructive pulmonary disease. Br J Pharmacol 178: 132‐151, 2021.
 65.Gredic M, Wu C‐Y, Hadzic S, Pak O, Savai R, Kojonazarov B, Doswada S, Weiss A, Weigert A, Guenther A, Brandes RP, Schermuly RT, Grimminger F, Seeger W, Sommer N, Kraut S, Weissmann N. Myeloid‐cell‐specific deletion of inducible nitric oxide synthase protects against smoke‐induced pulmonary hypertension in mice. Eur Respir J 59: 2101153, 2022.
 66.Guignabert C, Tu L, Le Hiress M, Ricard N, Sattler C, Seferian A, Huertas A, Humbert M, Montani D. Pathogenesis of pulmonary arterial hypertension: Lessons from cancer. Eur Respir Rev 22: 543‐551, 2013.
 67.Hainsworth R, Drinkhill MJ. Cardiovascular adjustments for life at high altitude. Respir Physiol Neurobiol 158: 204‐211, 2007.
 68.Harbaum L, Rhodes CJ, Wharton J, Lawrie A, Karnes JH, Desai AA, Nichols WC, Humbert M, Montani D, Girerd B, Sitbon O, Boehm M, Novoyatleva T, Schermuly RT, Ghofrani HA, Toshner M, Kiely DG, Howard LS, Swietlik EM, Graf S, Pietzner M, Morrell NW, Wilkins MR, U.K. National Institute for Health Research BioResource Rare Diseases Consortium UKPAHCSC, Consortium USPAHB. Mining the plasma proteome for insights into the molecular pathology of pulmonary arterial hypertension. Am J Respir Crit Care Med 205: 1449‐1460, 2022.
 69.Harrison RE, Berger R, Haworth SG, Tulloh R, Mache CJ, Morrell NW, Aldred MA, Trembath RC. Transforming growth factor‐beta receptor mutations and pulmonary arterial hypertension in childhood. Circulation 111: 435‐441, 2005.
 70.Hassoun PM, Mouthon L, Barbera JA, Eddahibi S, Flores SC, Grimminger F, Jones PL, Maitland ML, Michelakis ED, Morrell NW, Newman JH, Rabinovitch M, Schermuly R, Stenmark KR, Voelkel NF, Yuan JX, Humbert M. Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol 54: S10‐S19, 2009.
 71.Hatano S, Strasser T, and World Health Organization. Primary pulmonary hypertension: report on a WHO meeting, Geneva, 15‐17 October 1973/edited by Shuichi Hatano and Toma Strasser. Geneva: World Health Organization, 1975.
 72.Heath D, Edwards JE. The pathology of hypertensive pulmonary vascular disease; a description of six grades of structural changes in the pulmonary arteries with special reference to congenital cardiac septal defects. Circulation 18: 533‐547, 1958.
 73.Hemnes AR, Beck GJ, Newman JH, Abidov A, Aldred MA, Barnard J, Berman Rosenzweig E, Borlaug BA, Chung WK, SAA C, Erzurum SC, Frantz RP, Gray MP, Grunig G, Hassoun PM, Hill NS, Horn EM, Hu B, Lempel JK, Maron BA, Mathai SC, Olman MA, Rischard FP, Systrom DM, WHW T, Waxman AB, Xiao L, Yuan JX, Leopold JA, Group PS. PVDOMICS: A multi‐center study to improve understanding of pulmonary vascular disease through phenomics. Circ Res 121: 1136‐1139, 2017.
 74.Hochachka PW. Defense strategies against hypoxia and hypothermia. Science 231: 234‐241, 1986.
 75.Hoffmann J, Marsh LM, Pieper M, Stacher E, Ghanim B, Kovacs G, Konig P, Wilkens H, Haitchi HM, Hoefler G, Klepetko W, Olschewski H, Olschewski A, Kwapiszewska G. Compartment‐specific expression of collagens and their processing enzymes in intrapulmonary arteries of IPAH patients. Am J Physiol Lung Cell Mol Physiol 308: L1002‐L1013, 2015.
 76.Hoffmann J, Wilhelm J, Marsh LM, Ghanim B, Klepetko W, Kovacs G, Olschewski H, Olschewski A, Kwapiszewska G. Distinct differences in gene expression patterns in pulmonary arteries of patients with chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis with pulmonary hypertension. Am J Respir Crit Care Med 190: 98‐111, 2014.
 77.Huicho L. Postnatal cardiopulmonary adaptations to high altitude. Respir Physiol Neurobiol 158: 190‐203, 2007.
 78.Humbert M, Guignabert C, Bonnet S, Dorfmuller P, Klinger JR, Nicolls MR, Olschewski AJ, Pullamsetti SS, Schermuly RT, Stenmark KR, Rabinovitch M. Pathology and pathobiology of pulmonary hypertension: State of the art and research perspectives. Eur Respir J 53: 1801887, 2019.
 79.Humbert M, McLaughlin V, Gibbs JSR, Gomberg‐Maitland M, Hoeper MM, Preston IR, Souza R, Waxman A, Escribano Subias P, Feldman J, Meyer G, Montani D, Olsson KM, Manimaran S, Barnes J, Linde PG, de Oliveira PJ, Badesch DB, Investigators PT. Sotatercept for the treatment of pulmonary arterial hypertension. N Engl J Med 384: 1204‐1215, 2021.
 80.Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 351: 1425‐1436, 2004.
 81.Idiopathic Pulmonary Fibrosis Clinical Research Network, Zisman DA, Schwarz M, Anstrom KJ, Collard HR, Flaherty KR, Hunninghake GW. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med 363: 620‐628, 2010.
 82.International PPHC, Lane KB, Machado RD, Pauciulo MW, Thomson JR, Phillips JA 3rd, Loyd JE, Nichols WC, Trembath RC. Heterozygous germline mutations in BMPR2, encoding a TGF‐beta receptor, cause familial primary pulmonary hypertension. Nat Genet 26: 81‐84, 2000.
 83.Jonigk D, Golpon H, Bockmeyer CL, Maegel L, Hoeper MM, Gottlieb J, Nickel N, Hussein K, Maus U, Lehmann U, Janciauskiene S, Welte T, Haverich A, Rische J, Kreipe H, Laenger F. Plexiform lesions in pulmonary arterial hypertension composition, architecture, and microenvironment. Am J Pathol 179: 167‐179, 2011.
 84.Jonigk D, Stark H, Braubach P, Neubert L, Shin H‐o, Izykowski N, Welte T, Janciauskiene S, Warnecke G, Haverich A, Kuehnel M, Laenger F. Morphological and molecular motifs of fibrosing pulmonary injury patterns. J Pathol Clin Res 5: 256‐271, 2019.
 85.Kanwar MK, Gomberg‐Maitland M, Hoeper M, Pausch C, Pittow D, Strange G, Anderson JJ, Zhao C, Scott JV, Druzdzel MJ, Kraisangka J, Lohmueller L, Antaki J, Benza RL. Risk stratification in pulmonary arterial hypertension using Bayesian analysis. Eur Respir J 56: 2000008, 2020.
 86.Kariotis S, Jammeh E, Swietlik EM, Pickworth JA, Rhodes CJ, Otero P, Wharton J, Iremonger J, Dunning MJ, Pandya D, Mascarenhas TS, Errington N, AAR T, Romanoski CE, Rischard F, JGN G, JXJ Y, THS A, Desai AA, Coghlan G, Lordan J, Corris PA, Howard LS, Condliffe R, Kiely DG, Church C, Pepke‐Zaba J, Toshner M, Wort S, Gräf S, Morrell NW, Wilkins MR, Lawrie A, Wang D, Bleda M, Hadinnapola C, Haimel M, Auckland K, Tilly T, Martin JM, Yates K, Treacy CM, Day M, Greenhalgh A, Shipley D, Peacock AJ, Irvine V, Kennedy F, Moledina S, Macdonald L, Tamvaki E, Barnes A, Cookson V, Chentouf L, Ali S, Othman S, Ranganathan L, JSR G, Dacosta R, Pinguel J, Dormand N, Parker A, Stokes D, Ghedia D, Tan Y, Ngcozana T, Wanjiku I, Polwarth G, Mackenzie Ross RV, Suntharalingam J, Grover M, Kirby A, Grove A, White K, Seatter A, Creaser‐Myers A, Walker S, Roney S, Elliot CA, Charalampopoulos A, Sabroe I, Hameed A, Armstrong I, Hamilton N, AMK R, Swift AJ, Wild JM, Soubrier F, Eyries M, Humbert M, Montani D, Girerd B, Scelsi L, Ghio S, Gall H, Ghofrani A, Bogaard HJ, Noordegraaf AV, Houweling AC, AHIT V, Schotte G. Biological heterogeneity in idiopathic pulmonary arterial hypertension identified through unsupervised transcriptomic profiling of whole blood. Nat Commun 12: 7104, 2021.
 87.Kessler R, Faller M, Weitzenblum E, Chaouat A, Aykut A, Ducoloné A, Ehrhart M, Oswald‐Mammosser M. “Natural History” of pulmonary hypertension in a series of 131 patients with chronic obstructive lung disease. Am J Respir Crit Care Med 162: 219‐224, 2001.
 88.Kessler RFM, Fourgaut G, Mennecier B, Weitzenblum E. Predictive factors of hospitalization for acute exacerbation in a series of 64 patietns with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 159: 158‐164, 1999.
 89.Kheyfets VO, Schafer M, Podgorski CA, Schroeder JD, Browning J, Hertzberg J, Buckner JK, Hunter KS, Shandas R, Fenster BE. 4D Magnetic resonance flow imaging for estimating pulmonary vascular resistance in pulmonary hypertension. J Magn Reson Imaging 44: 914‐922, 2016.
 90.Kheyfets VO, Sucharov CC, Truong U, Dunning J, Hunter K, Ivy D, Miyamoto S, Shandas R. Circulating miRNAs in pediatric pulmonary hypertension show promise as biomarkers of vascular function. Oxidative Med Cell Longev 2017: 4957147, 2017.
 91.Kheyfets VO, Sweatt A, Gomberg-Maitland M, Ivy D, Kiely D, Lawrie A, Zamanian R, Stemark K. Computational platform for doctor-AI cooperation in AI prognostication: A pilot study. ERJ Open Research Submitted Sept 24 2022. In Press.
 92.Kiely DG, Doyle O, Drage E, Jenner H, Salvatelli V, Daniels FA, Rigg J, Schmitt C, Samyshkin Y, Lawrie A, Bergemann R. Utilising artificial intelligence to determine patients at risk of a rare disease: Idiopathic pulmonary arterial hypertension. Pulm Circ 9: 2045894019890549, 2019.
 93.Kimura M, Taniguchi H, Kondoh Y, Kimura T, Kataoka K, Nishiyama O, Aso H, Sakamoto K, Hasegawa Y. Pulmonary hypertension as a prognostic indicator at the initial evaluation in idiopathic pulmonary fibrosis. Respiration 85: 456‐463, 2013.
 94.King CS, Shlobin OA. The trouble with group 3 pulmonary hypertension in interstitial lung disease: Dilemmas in diagnosis and the conundrum of treatment. Chest 158: 1651‐1664, 2020.
 95.King TE Jr, Behr J, Brown KK, du Bois RM, Lancaster L, de Andrade JA, Stahler G, Leconte I, Roux S, Raghu G. BUILD‐1: A randomized placebo‐controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 177: 75‐81, 2008.
 96.Kissinger H, Schmidt E, Huttenlocher DP, Schouten S. The Age of AI: And our Human Future. New York: Little Brown and Company, 2021, p. ix, 254 pages.
 97.Kovacs G, Berghold A, Scheidl S, Olschewski H. Pulmonary arterial pressure during rest and exercise in healthy subjects: A systematic review. Eur Respir J 34: 888‐894, 2009.
 98.Krenz GS, Dawson CA. Flow and pressure distributions in vascular networks consisting of distensible vessels. Am J Physiol Heart Circ Physiol 284: H2192‐H2203, 2003.
 99.Kubo K, Ge RL, Koizumi T, Fujimoto K, Yamanda T, Haniuda M, Honda T. Pulmonary artery remodeling modifies pulmonary hypertension during exercise in severe emphysema. Respir Physiol 120: 71‐79, 2000.
 100.Kumar R, Mickael C, Kassa B, Sanders L, Hernandez‐Saavedra D, Koyanagi DE, Kumar S, Pugliese SC, Thomas S, McClendon J, Maloney JP, Janssen WJ, Stenmark KR, Tuder RM, Graham BB. Interstitial macrophage‐derived thrombospondin‐1 contributes to hypoxia‐induced pulmonary hypertension. Cardiovasc Res 116: 2021‐2030, 2020.
 101.Lan B, Hayama E, Kawaguchi N, Furutani Y, Nakanishi T. Therapeutic efficacy of valproic acid in a combined monocrotaline and chronic hypoxia rat model of severe pulmonary hypertension. PLoS One 10: e0117211, 2015.
 102.Lee SD, Shroyer KR, Markham NE, Cool CD, Voelkel NF, Tuder RM. Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension. J Clin Investig 101: 927‐934, 1998.
 103.León‐Velarde F, Maggiorini M, Reeves JT, Aldashev A, Asmus I, Bernardi L, Ge RL, Hackett P, Kobayashi T, Moore LG, Penaloza D, Richalet JP, Roach R, Wu T, Vargas E, Zubieta‐Castillo G, Zubieta‐Calleja G. Consensus statement on chronic and subacute high altitude diseases. High Alt Med Biol 6: 147‐157, 2005.
 104.León‐Velarde F, Villafuerte FC, Richalet JP. Chronic mountain sickness and the heart. Prog Cardiovasc Dis 52: 540‐549, 2010.
 105.Leopold JA, Maron BA, Loscalzo J. The application of big data to cardiovascular disease: Paths to precision medicine. J Clin Invest 130: 29‐38, 2020.
 106.Lettieri CJ, Nathan SD, Barnett SD, Ahmad S, Shorr AF. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest 129: 746‐752, 2006.
 107.Lewis GD, Ngo D, Hemnes AR, Farrell L, Domos C, Pappagianopoulos PP, Dhakal BP, Souza A, Shi X, Pugh ME, Beloiartsev A, Sinha S, Clish CB, Gerszten RE. Metabolic profiling of right ventricular‐pulmonary vascular function reveals circulating biomarkers of pulmonary hypertension. J Am Coll Cardiol 67: 174‐189, 2016.
 108.Lichtblau M, Saxer S, Furian M, Mayer L, Bader PR, Scheiwiller PM, Mademilov M, Sheraliev U, Tanner FC, Sooronbaev TM, Bloch KE, Ulrich S. Cardiac function and pulmonary hypertension in Central Asian highlanders at 3250 m. Eur Respir J 56: 1902474, 2020.
 109.Lin S, Du L. The therapeutic potential of BRD4 in cardiovascular disease. Hypertens Res 43: 1006‐1014, 2020.
 110.Liu X, Zhang S, Wang X, Wang Y, Song J, Sun C, Chen G, Yang G, Tao Y, Hu Y, Bu D, Huang Y, Du J, Jin H. Endothelial cell‐derived SO(2) controls endothelial cell inflammation, smooth muscle cell proliferation, and collagen synthesis to inhibit hypoxic pulmonary vascular remodelling. Oxidative Med Cell Longev 2021: 5577634, 2021.
 111.Long L, Ormiston ML, Yang X, Southwood M, Graf S, Machado RD, Mueller M, Kinzel B, Yung LM, Wilkinson JM, Moore SD, Drake KM, Aldred MA, Yu PB, Upton PD, Morrell NW. Selective enhancement of endothelial BMPR‐II with BMP9 reverses pulmonary arterial hypertension. Nat Med 21: 777‐785, 2015.
 112.Machado RD, Southgate L, Eichstaedt CA, Aldred MA, Austin ED, Best DH, Chung WK, Benjamin N, Elliott CG, Eyries M, Fischer C, Graf S, Hinderhofer K, Humbert M, Keiles SB, Loyd JE, Morrell NW, Newman JH, Soubrier F, Trembath RC, Viales RR, Grunig E. Pulmonary arterial hypertension: A current perspective on established and emerging molecular genetic defects. Hum Mutat 36: 1113‐1127, 2015.
 113.Magee F, Wright JL, Wiggs BR, Pare PD, Hogg JC. Pulmonary vascular structure and function in chronic obstructive pulmonary disease. Thorax 43: 183‐189, 1988.
 114.Masri FA, Xu W, Comhair SA, Asosingh K, Koo M, Vasanji A, Drazba J, nand‐Apte B, and Erzurum SC. Hyperproliferative apoptosis‐resistant endothelial cells in idiopathic pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol 293: L548‐L554, 2007.
 115.Maston LD, Jones DT, Giermakowska W, Resta TC, Ramiro‐Diaz J, Howard TA, Jernigan NL, Herbert L, Maurice AA, Gonzalez Bosc LV. Interleukin‐6 trans‐signaling contributes to chronic hypoxia‐induced pulmonary hypertension. Pulm Circ 8: 2045894018780734, 2018.
 116.Meloche J, Potus F, Vaillancourt M, Bourgeois A, Johnson I, Deschamps L, Chabot S, Ruffenach G, Henry S, Breuils‐Bonnet S, Tremblay E, Nadeau V, Lambert C, Paradis R, Provencher S, Bonnet S. Bromodomain‐containing protein 4: The epigenetic origin of pulmonary arterial hypertension. Circ Res 117: 525‐535, 2015.
 117.Meyrick B, Reid L. Hypoxia‐induced structural changes in the media and adventitia of the rat hilar pulmonary artery and their regression. Am J Pathol 100: 151‐178, 1980.
 118.Michelakis ED, Gurtu V, Webster L, Barnes G, Watson G, Howard L, Cupitt J, Paterson I, Thompson RB, Chow K, O'Regan DP, Zhao L, Wharton J, Kiely DG, Kinnaird A, Boukouris AE, White C, Nagendran J, Freed DH, Wort SJ, Gibbs JSR, Wilkins MR. Inhibition of pyruvate dehydrogenase kinase improves pulmonary arterial hypertension in genetically susceptible patients. Sci Transl Med 9: eaao4583, 2017.
 119.Minai OA, Chaouat A, Adnot S. Pulmonary hypertension in COPD: Epidemiology, significance, and management: Pulmonary vascular disease: The global perspective. Chest 137: 39S‐51S, 2010.
 120.Minai OA, Santacruz JF, Alster JM, Budev MM, McCarthy K. Impact of pulmonary hemodynamics on 6‐min walk test in idiopathic pulmonary fibrosis. Respir Med 106: 1613‐1621, 2012.
 121.Moudgil R, Michelakis ED, Archer SL. Hypoxic pulmonary vasoconstriction. J Appl Physiol (1985) 98: 390‐403, 2005.
 122.Nadrous HF, Pellikka PA, Krowka MJ, Swanson KL, Chaowalit N, Decker PA, Ryu JH. Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Chest 128: 2393‐2399, 2005.
 123.Naeije R, Chesler N. Pulmonary circulation at exercise. Compr Physiol 2: 711‐741, 2012.
 124.Nasim MT, Ogo T, Ahmed M, Randall R, Chowdhury HM, Snape KM, Bradshaw TY, Southgate L, Lee GJ, Jackson I, Lord GM, Gibbs JS, Wilkins MR, Ohta‐Ogo K, Nakamura K, Girerd B, Coulet F, Soubrier F, Humbert M, Morrell NW, Trembath RC, Machado RD. Molecular genetic characterization of SMAD signaling molecules in pulmonary arterial hypertension. Hum Mutat 32: 1385‐1389, 2011.
 125.Nathan SD, Behr J, Collard HR, Cottin V, Hoeper MM, Martinez FJ, Corte TJ, Keogh AM, Leuchte H, Mogulkoc N, Ulrich S, Wuyts WA, Yao Z, Boateng F, Wells AU. Riociguat for idiopathic interstitial pneumonia‐associated pulmonary hypertension (RISE‐IIP): A randomised, placebo‐controlled phase 2b study. Lancet Respir Med 7: 780‐790, 2019.
 126.Nathan SD, Shlobin OA, Ahmad S, Koch J, Barnett SD, Ad N, Burton N, Leslie K. Serial development of pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Respiration 76: 288‐294, 2008.
 127.Negi PC, Marwaha R, Asotra S, Kandoria A, Ganju N, Sharma R, Kumar RV, Bhardwaj R. Prevalence of high altitude pulmonary hypertension among the natives of Spiti Valley—a high altitude region in Himachal Pradesh, India. High Alt Med Biol 15: 504‐510, 2014.
 128.Neubert L, Borchert P, Stark H, Hoefer A, Vogel‐Claussen J, Warnecke G, Eubel H, Kuenzler P, Kreipe HH, Hoeper MM, Kuehnel M, Jonigk D. Molecular Profiling of Vascular Remodeling in Chronic Pulmonary Disease. Am J Pathol 190: 1382‐1396, 2020.
 129.Oldham WM, Hess E, Waldo SW, Humbert M, Choudhary G, Maron BA. Integrating haemodynamics identifies an extreme pulmonary hypertension phenotype. Eur Respir J 58: 2004625, 2021.
 130.Oldham WM, Oliveira RKF, Wang RS, Opotowsky AR, Rubins DM, Hainer J, Wertheim BM, Alba GA, Choudhary G, Tornyos A, MacRae CA, Loscalzo J, Leopold JA, Waxman AB, Olschewski H, Kovacs G, Systrom DM, Maron BA. Network analysis to risk stratify patients with exercise intolerance. Circ Res 122: 864‐876, 2018.
 131.Oswald‐Mammosser M, Weitzenblum E, Quoix E, Moser G, Chaouat A, Charpentier C, Kessler R. Prognostic factors in COPD patients receiving long‐term oxygen therapy. Importance of pulmonary artery pressure. Chest 107: 1193‐1198, 1995.
 132.Parra ER, David YR, da Costa LR, Ab'Saber A, Sousa R, Kairalla RA, de Carvalho CR, Filho MT, Capelozzi VL. Heterogeneous remodeling of lung vessels in idiopathic pulmonary fibrosis. Lung 183: 291‐300, 2005.
 133.Patel NM, Kawut SM, Jelic S, Arcasoy SM, Lederer DJ, Borczuk AC. Pulmonary arteriole gene expression signature in idiopathic pulmonary fibrosis. Eur Respir J 41: 1324‐1330, 2013.
 134.Penaloza D, Arias‐Stella J. The heart and pulmonary circulation at high altitudes: Healthy highlanders and chronic mountain sickness. Circulation 115: 1132‐1146, 2007.
 135.Polverino F, Laucho‐Contreras ME, Petersen H, Bijol V, Sholl LM, Choi ME, Divo M, Pinto‐Plata V, Chetta A, Tesfaigzi Y, Celli BR, Owen CA. A pilot study linking endothelial injury in lungs and kidneys in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 195: 1464‐1476, 2017.
 136.Potus F, Pauciulo MW, Cook EK, Zhu N, Hsieh A, Welch CL, Shen Y, Tian L, Lima P, Mewburn J, D'Arsigny CL, Lutz KA, Coleman AW, Damico R, Snetsinger B, Martin AY, Hassoun PM, Nichols WC, Chung WK, Rauh MJ, Archer SL. Novel mutations and decreased expression of the epigenetic regulator TET2 in pulmonary arterial hypertension. Circulation 141: 1986‐2000, 2020.
 137.Potus F, Ruffenach G, Dahou A, Thebault C, Breuils‐Bonnet S, Tremblay E, Nadeau V, Paradis R, Graydon C, Wong R, Johnson I, Paulin R, Lajoie AC, Perron J, Charbonneau E, Joubert P, Pibarot P, Michelakis ED, Provencher S, Bonnet S. Downregulation of MicroRNA‐126 contributes to the failing right ventricle in pulmonary arterial hypertension. Circulation 132: 932‐943, 2015.
 138.Prins KW, Rose L, Archer SL, Pritzker M, Weir EK, Kazmirczak F, Misialek JR, Thenappan T. Disproportionate Right Ventricular Dysfunction and Poor Survival in Group 3 Pulmonary Hypertension. Am J Respir Crit Care Med 197: 1496‐1499, 2018.
 139.Pu X, Lin X, Duan X, Wang J, Shang J, Yun H, Chen Z. Oxidative and endoplasmic reticulum stress responses to chronic high‐altitude exposure during the development of high‐altitude pulmonary hypertension. High Alt Med Biol 21: 378‐387, 2020.
 140.Pullamsetti SS, Savai R, Seeger W, Goncharova EA. Translational advances in the field of pulmonary hypertension. From cancer biology to new pulmonary arterial hypertension therapeutics. Targeting cell growth and proliferation signaling hubs. Am J Respir Crit Care Med 195: 425‐437, 2017.
 141.Rabinovitch M. Investigational approaches to pulmonary hypertension. Toxicol Pathol 19: 458‐469, 1991.
 142.Rabinovitch M, Gamble W, Nadas AS, Miettinen OS, Reid L. Rat pulmonary circulation after chronic hypoxia: Hemodynamic and structural features. Am J Phys 236: H818‐H827, 1979.
 143.Rabinovitch M, Gamble WJ, Miettinen OS, Reid L. Age and sex influence on pulmonary hypertension of chronic hypoxia and on recovery. Am J Phys 240: H62‐H72, 1981.
 144.Rabinovitch M, Konstam MA, Gamble WJ, Papanicolaou N, Aronovitz MJ, Treves S, Reid L. Changes in pulmonary blood flow affect vascular response to chronic hypoxia in rats. Circ Res 52: 432‐441, 1983.
 145.Raghu G, Behr J, Brown KK, Egan JJ, Kawut SM, Flaherty KR, Martinez FJ, Nathan SD, Wells AU, Collard HR, Costabel U, Richeldi L, de Andrade J, Khalil N, Morrison LD, Lederer DJ, Shao L, Li X, Pedersen PS, Montgomery AB, Chien JW, O'Riordan TG, ARTEMIS‐IPF Investigators. Treatment of idiopathic pulmonary fibrosis with ambrisentan: A parallel, randomized trial. Ann Intern Med 158: 641‐649, 2013.
 146.Raghu G, Million‐Rousseau R, Morganti A, Perchenet L, Behr J, Group MS. Macitentan for the treatment of idiopathic pulmonary fibrosis: The randomised controlled MUSIC trial. Eur Respir J 42: 1622‐1632, 2013.
 147.Rai PR, Cool CD, King JAC, Stevens T, Burns N, Winn RA, Kasper M, Voelkel NF. The cancer paradigm of severe pulmonary arterial hypertension. Am J Respir Crit Care Med 178: 558‐564, 2008.
 148.Rao RS, Singh S, Sharma BB, Agarwal VV, Singh V. Sildenafil improves six‐minute walk distance in chronic obstructive pulmonary disease: A randomised, double‐blind, placebo‐controlled trial. Indian J Chest Dis Allied Sci 53: 81‐85, 2011.
 149.Reeves JT, Rubin LJ. The pulmonary circulation: Snapshots of progress. Am J Respir Crit Care Med 157: S101‐S108, 1998.
 150.Remillard CV, Yuan JX. High altitude pulmonary hypertension: Role of K+ and Ca2+ channels. High Alt Med Biol 6: 133‐146, 2005.
 151.Rhodes CJ, Ghataorhe P, Wharton J, Rue‐Albrecht KC, Hadinnapola C, Watson G, Bleda M, Haimel M, Coghlan G, Corris PA, Howard LS, Kiely DG, Peacock AJ, Pepke‐Zaba J, Toshner MR, Wort SJ, Gibbs JS, Lawrie A, Graf S, Morrell NW, Wilkins MR. Plasma metabolomics implicates modified transfer RNAs and altered bioenergetics in the outcomes of pulmonary arterial hypertension. Circulation 135: 460‐475, 2017.
 152.Rhodes CJ, Sweatt AJ, Maron BA. Harnessing big data to advance treatment and understanding of pulmonary hypertension. Circ Res 130: 1423‐1444, 2022.
 153.Rhodes CJ, Wharton J, Ghataorhe P, Watson G, Girerd B, Howard LS, Gibbs JSR, Condliffe R, Elliot CA, Kiely DG, Simonneau G, Montani D, Sitbon O, Gall H, Schermuly RT, Ghofrani HA, Lawrie A, Humbert M, Wilkins MR. Plasma proteome analysis in patients with pulmonary arterial hypertension: An observational cohort study. Lancet Respir Med 5: 717‐726, 2017.
 154.Rothman AM, Arnold ND, Pickworth JA, Iremonger J, Ciuclan L, Allen RM, Guth‐Gundel S, Southwood M, Morrell NW, Thomas M, Francis SE, Rowlands DJ, Lawrie A. MicroRNA‐140‐5p and SMURF1 regulate pulmonary arterial hypertension. J Clin Invest 126: 2495‐2508, 2016.
 155.Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, Landzberg M, Simonneau G. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346: 896‐903, 2002.
 156.Ryu JH, Krowka MJ, Pellikka PA, Swanson KL, McGoon MD. Pulmonary hypertension in patients with interstitial lung diseases. Mayo Clin Proc 82: 342‐350, 2007.
 157.Sakao S, Voelkel NF, Tatsumi K. The vascular bed in COPD: Pulmonary hypertension and pulmonary vascular alterations. Eur Respir Rev 23: 350‐355, 2014.
 158.Santos S, Peinado VI, Ramirez J, Melgosa T, Roca J, Rodriguez‐Roisin R, Barbera JA. Characterization of pulmonary vascular remodelling in smokers and patients with mild COPD. Eur Respir J 19: 632‐638, 2002.
 159.Sastry BK, Narasimhan C, Reddy NK, Raju BS. Clinical efficacy of sildenafil in primary pulmonary hypertension: A randomized, placebo‐controlled, double‐blind, crossover study. J Am Coll Cardiol 43: 1149‐1153, 2004.
 160.Savai R, Pullamsetti SS, Kolbe J, Bieniek E, Voswinckel R, Fink L, Scheed A, Ritter C, Dahal BK, Vater A. Immune and inflammatory cell involvement in the pathology of idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 186: 897‐908, 2012.
 161.Savale L, Tu L, Rideau D, Izziki M, Maitre B, Adnot S, Eddahibi S. Impact of interleukin‐6 on hypoxia‐induced pulmonary hypertension and lung inflammation in mice. Respir Res 10: 6, 2009.
 162.Seimetz M, Parajuli N, Pichl A, Veit F, Kwapiszewska G, Weisel FC, Milger K, Egemnazarov B, Turowska A, Fuchs B, Nikam S, Roth M, Sydykov A, Medebach T, Klepetko W, Jaksch P, Dumitrascu R, Garn H, Voswinckel R, Kostin S, Seeger W, Schermuly RT, Grimminger F, Ghofrani HA, Weissmann N. Inducible NOS inhibition reverses tobacco‐smoke‐induced emphysema and pulmonary hypertension in mice. Cell 147: 293‐305, 2011.
 163.Shah SJ, Katz DH, Selvaraj S, Burke MA, Yancy CW, Gheorghiade M, Bonow RO, Huang CC, Deo RC. Phenomapping for novel classification of heart failure with preserved ejection fraction. Circulation 131: 269‐279, 2015.
 164.Sheikh AQ, Saddouk FZ, Ntokou A, Mazurek R, Greif DM. Cell autonomous and non‐cell autonomous regulation of SMC progenitors in pulmonary hypertension. Cell Rep 23: 1152‐1165, 2018.
 165.Shi L, Kojonazarov B, Elgheznawy A, Popp R, Dahal BK, Bohm M, Pullamsetti SS, Ghofrani HA, Godecke A, Jungmann A, Katus HA, Muller OJ, Schermuly RT, Fisslthaler B, Seeger W, Fleming I. miR‐223‐IGF‐IR signalling in hypoxia‐ and load‐induced right‐ventricular failure: A novel therapeutic approach. Cardiovasc Res 111: 184‐193, 2016.
 166.Shorr AF, Wainright JL, Cors CS, Lettieri CJ, Nathan SD. Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant. Eur Respir J 30: 715‐721, 2007.
 167.Simonneau G, Galie N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, Gibbs S, Lebrec D, Speich R, Beghetti M, Rich S, Fishman A. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 43: 5S‐12S, 2004.
 168.Siques P, Pena E, Brito J, El Alam S. Oxidative stress, kinase activation, and inflammatory pathways involved in effects on smooth muscle cells during pulmonary artery hypertension under hypobaric hypoxia exposure. Front Physiol 12: 690341, 2021.
 169.Sitbon O, Humbert M, Jagot JL, Taravella O, Fartoukh M, Parent F, Herve P, Simonneau G. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium‐channel blockers in primary pulmonary hypertension. Eur Respir J 12: 265‐270, 1998.
 170.Sitbon O, Humbert M, Jais X, Ioos V, Hamid AM, Provencher S, Garcia G, Parent F, Herve P, Simonneau G. Long‐term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 111: 3105‐3111, 2005.
 171.Sobin SS, Tremer HM, Hardy JD, Chiodi HP. Changes in arteriole in acute and chronic hypoxic pulmonary hypertension and recovery in rat. J Appl Physiol Respir Environ Exerc Physiol 55: 1445‐1455, 1983.
 172.Soria R, Egger M, Scherrer U, Bender N, Rimoldi SF. Pulmonary artery pressure and arterial oxygen saturation in people living at high or low altitude: Systematic review and meta‐analysis. J Appl Physiol (1985) 121: 1151‐1159, 2016.
 173.Spiekerkoetter E, Goncharova EA, Guignabert C, Stenmark K, Kwapiszewska G, Rabinovitch M, Voelkel N, Bogaard HJ, Graham B, Pullamsetti SS, Kuebler WM. Hot topics in the mechanisms of pulmonary arterial hypertension disease: Cancer‐like pathobiology, the role of the adventitia, systemic involvement, and right ventricular failure. Pulm Circ 9: 2045894019889775, 2019.
 174.Spiekerkoetter E, Sung YK, Sudheendra D, Scott V, Del Rosario P, Bill M, Haddad F, Long‐Boyle J, Hedlin H, Zamanian RT. Randomised placebo‐controlled safety and tolerability trial of FK506 (tacrolimus) for pulmonary arterial hypertension. Eur Respir J 50, 2017.
 175.Spiekerkoetter E, Tian X, Cai J, Hopper RK, Sudheendra D, Li CG, El‐Bizri N, Sawada H, Haghighat R, Chan R, Haghighat L, de Jesus PV, Wang L, Reddy S, Zhao M, Bernstein D, Solow‐Cordero DE, Beachy PA, Wandless TJ, Ten Dijke P, Rabinovitch M. FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension. J Clin Invest 123: 3600‐3613, 2013.
 176.Stacher E, Graham BB, Hunt JM, Gandjeva A, Groshong SD, McLaughlin VV, Jessup M, Grizzle WE, Aldred MA, Cool CD, Tuder RM. Modern age pathology of pulmonary arterial hypertension. Am J Respir Crit Care Med 186: 261‐272, 2012.
 177.Stenmark KR, Fagan KA, Frid MG. Hypoxia‐induced pulmonary vascular remodeling: Cellular and molecular mechanisms. Circ Res 99: 675‐691, 2006.
 178.Stenmark KR, Frid MG, Graham BB, Tuder RM. Dynamic and diverse changes in the functional properties of vascular smooth muscle cells in pulmonary hypertension. Cardiovasc Res 114: 551‐564, 2018.
 179.Stenmark KR, McMurtry IF. Vascular remodeling versus vasoconstriction in chronic hypoxic pulmonary hypertension: A time for reappraisal? Circ Res 97: 95‐98, 2005.
 180.Stenmark KR, Mecham RP. Cellular and molecular mechanisms of pulmonary vascular remodeling. Annu Rev Physiol 59: 89‐144, 1997.
 181.Stokes JM, Yang K, Swanson K, Jin W, Cubillos‐Ruiz A, Donghia NM, MacNair CR, French S, Carfrae LA, Bloom‐Ackermann Z, Tran VM, Chiappino‐Pepe A, Badran AH, Andrews IW, Chory EJ, Church GM, Brown ED, Jaakkola TS, Barzilay R, Collins JJ. A deep learning approach to antibiotic discovery. Cell 180: 688‐702 e613, 2020.
 182.Stolz D, Rasch H, Linka A, Di Valentino M, Meyer A, Brutsche M, Tamm M. A randomised, controlled trial of bosentan in severe COPD. Eur Respir J 32: 619‐628, 2008.
 183.Sturrock A, Cahill B, Norman K, Huecksteadt TP, Hill K, Sanders K, Karwande SV, Stringham JC, Bull DA, Gleich M, Kennedy TP, Hoidal JR. Transforming growth factor‐beta1 induces Nox4 NAD(P)H oxidase and reactive oxygen species‐dependent proliferation in human pulmonary artery smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 290: L661‐L673, 2006.
 184.Sweatt AJ, Hedlin HK, Balasubramanian V, Hsi A, Blum LK, Robinson WH, Haddad F, Hickey PM, Condliffe R, Lawrie A, Nicolls MR, Rabinovitch M, Khatri P, Zamanian RT. Discovery of distinct immune phenotypes using machine learning in pulmonary arterial hypertension. Circ Res 124: 904‐919, 2019.
 185.Swietlik EM, Ghataorhe P, Zalewska KI, Wharton J, Howard LS, Taboada D, Cannon JE, UKNCSo PAH, Morrell NW, Wilkins MR, Toshner M, Pepke‐Zaba J, Rhodes CJ. Plasma metabolomics exhibit response to therapy in chronic thromboembolic pulmonary hypertension. Eur Respir J 57: 2003201, 2021.
 186.Sylvester JT, Shimoda LA, Aaronson PI, Ward JP. Hypoxic pulmonary vasoconstriction. Physiol Rev 92: 367‐520, 2012.
 187.Sysol JR, Machado RF. Classification and pathophysiology of pulmonary hypertension. Contin Cardiol Educ 4: 2‐12, 2018.
 188.Taraseviciene‐Stewart L, Kasahara Y, Alger L, Hirth P, Mahon GM, Waltenberger J, Voelkel NF, Tuder RM. Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death‐dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J 15: 427‐438, 2001.
 189.Taraseviciene‐Stewart L, Voelkel NF. Molecular pathogenesis of emphysema. J Clin Invest 118: 394‐402, 2008.
 190.Thenappan T, Chan SY, Weir EK. Role of extracellular matrix in the pathogenesis of pulmonary arterial hypertension. Am J Physiol Heart Circ Physiol 315: H1322‐H1331, 2018.
 191.Thenappan T, Ormiston ML, Ryan JJ, Archer SL. Pulmonary arterial hypertension: Pathogenesis and clinical management. BMJ 360: j5492, 2018.
 192.Toba M, Alzoubi A, O'Neill KD, Gairhe S, Matsumoto Y, Oshima K, Abe K, Oka M, McMurtry IF. Temporal hemodynamic and histological progression in Sugen5416/hypoxia/normoxia‐exposed pulmonary arterial hypertensive rats. Am J Physiol Heart Circ Physiol 306: H243‐H250, 2014.
 193.Trembath RC, Thomson JR, Machado RD, Morgan NV, Atkinson C, Winship I, Simonneau G, Galie N, Loyd JE, Humbert M, Nichols WC, Morrell NW, Berg J, Manes A, McGaughran J, Pauciulo M, Wheeler L. Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J Med 345: 325‐334, 2001.
 194.Tuder RM. How do we measure pathology in PAH (lung and RV) and what does it tell us about the disease. Drug Discov Today 19: 1257‐1263, 2014.
 195.Tuder RM. Pulmonary vascular remodeling in pulmonary hypertension. Cell Tissue Res 367: 643‐649, 2017.
 196.Tuder RM, Chacon M, Alger LA, Wang J, Taraseviciene‐Stewart L, Kasahara Y, Cool CD, Bishop AE, Geraci MW, Semenza GL, Yacoub M, Polak JM, Voelkel NF. Expression of angiogenesis‐related molecules in plexiform lesions in severe pulmonary hypertension: Evidence for a process of disordered angiogenesis. J Pathol 195: 367‐374, 2001.
 197.Tuder RM, Cool CD. Pulmonary arteries and microcirculation in COPD with pulmonary hypertension: Bystander or culprit? Chest 156: 4‐6, 2019.
 198.Tuder RM, Davis LA, Graham BB. Targeting energetic Metabolism. Am J Respir Crit Care Med 185: 260‐266, 2012.
 199.Tuder RM, Groves BM, Badesch DB, Voelkel NF. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol 144: 275‐285, 1994.
 200.Tuder RM, Marecki JC, Richter A, Fijalkowska I, Flores S. Pathology of pulmonary hypertension. Clin Chest Med 28: 23‐42, vii, 2007.
 201.Tuder RM, Petrache I. Pathogenesis of chronic obstructive pulmonary disease. J Clin Invest 122: 2749‐2755, 2012.
 202.Tuder RM, Radisavljevic Z, Shroyer KR, Polak JM, Voelkel NF. Monoclonal endothelial cells in appetite suppressant‐associated pulmonary hypertension. Am J Respir Crit Care Med 158: 1999‐2001, 1998.
 203.Tuder RM, Stacher E, Robinson J, Kumar R, Graham BB. Pathology of pulmonary hypertension. Clin Chest Med 34: 639‐650, 2013.
 204.Tuder RM, Stenmark KR. Perspective: Pathobiological paradigms in pulmonary hypertension, time for reappraisal. Am J Physiol Lung Cell Mol Physiol 318: L1131‐L1137, 2020.
 205.United Therapeutics Corporation. United Therapeutics announces INCREASE study of Tyvaso ® meets primary and all secondary endpoints https://www.prnewswire.com/news‐releases/united‐therapeutics‐announces‐increase‐study‐of‐tyvaso‐meets‐primary‐and‐all‐secondary‐endpoints‐301009562.html. [2/22/2022], 2022.
 206.Valerio G, Bracciale P, Grazia D'AA. Effect of bosentan upon pulmonary hypertension in chronic obstructive pulmonary disease. Ther Adv Respir Dis 3: 15‐21, 2009.
 207.van der Have O, Westöö C, Ahrné F, Tian X, Ichimura K, Dreier T, Norvik C, Kumar ME, Spiekerkoetter E, Tran‐Lundmark K. Shunt‐type plexiform lesions identified in the Sugen5416/hypoxia rat model of pulmonary arterial hypertension using synchrotron‐based phase‐contrast micro‐CT. Eur Respir J 59: 2102802, 2022.
 208.Van Goor F, Straley KS, Cao D, Gonzalez J, Hadida S, Hazlewood A, Joubran J, Knapp T, Makings LR, Miller M, Neuberger T, Olson E, Panchenko V, Rader J, Singh A, Stack JH, Tung R, Grootenhuis PD, Negulescu P. Rescue of DeltaF508‐CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am J Physiol Lung Cell Mol Physiol 290: L1117‐L1130, 2006.
 209.van Suylen RJ, Smits JF, Daemen MJ. Pulmonary artery remodeling differs in hypoxia‐ and monocrotaline‐induced pulmonary hypertension. Am J Respir Crit Care Med 157: 1423‐1428, 1998.
 210.Vitulo P, Stanziola A, Confalonieri M, Libertucci D, Oggionni T, Rottoli P, Paciocco G, Tuzzolino F, Martino L, Beretta M, Callari A, Amaducci A, Badagliacca R, Poscia R, Meloni F, Refini RM, Geri P, Baldi S, Ghio S, D'Alto M, Argiento P, Sofia M, Guardamagna M, Pezzuto B, Vizza CD. Sildenafil in severe pulmonary hypertension associated with chronic obstructive pulmonary disease: A randomized controlled multicenter clinical trial. J Heart Lung Transplant 36: 166‐174, 2017.
 211.Voelkel NF, Cool CD, Lee SD, Wright L, Geraci MW, Tuder RM. Primary pulmonary hypertension between inflammation and cancer. Chest 114: 225S‐230S, 1999.
 212.Voelkel NF, Tuder RM. Hypoxia‐induced pulmonary vascular remodeling—A model for what human disease? J Clin Investig 106: 733‐738, 2000.
 213.Vonbank K, Ziesche R, Higenbottam TW, Stiebellehner L, Petkov V, Schenk P, Germann P, Block LH. Controlled prospective randomised trial on the effects on pulmonary haemodynamics of the ambulatory long term use of nitric oxide and oxygen in patients with severe COPD. Thorax 58: 289‐293, 2003.
 214.Voosen P. The AI detectives. Science 357: 22‐27, 2017.
 215.Wagenvoort CA, Wagenvoort N. Pulmonary veins in high‐altitude residents: A morphometric study. Thorax 37: 931‐935, 1982.
 216.Wang A, Valdez‐Jasso D. Cellular mechanosignaling in pulmonary arterial hypertension. Biophys Rev 13: 747‐756, 2021.
 217.Wang X, Guo Z, Ding Z, Mehta JL. Inflammation, autophagy, and apoptosis after myocardial infarction. J Am Heart Assoc 7: e008024, 2018.
 218.Washko GR, Nardelli P, Ash SY, Vegas Sanchez‐Ferrero G, Rahaghi FN, Come CE, Dransfield MT, Kalhan R, Han MK, Bhatt SP, Wells JM, Aaron CP, Diaz AA, Ross JC, Cuttica MJ, Labaki WW, Querejeta Roca G, Shah AM, Young K, Kinney GL, Hokanson JE, Agusti A, San Jose Estepar R. Arterial vascular pruning, right ventricular size, and clinical outcomes in chronic obstructive pulmonary disease. A longitudinal observational study. Am J Respir Crit Care Med 200: 454‐461, 2019.
 219.Watkins WD, Peterson MB, Crone RK, Shannon DC, Levine L. Prostacyclin and prostaglandin E1 for severe idiopathic pulmonary artery hypertension. Lancet 1: 1083, 1980.
 220.Waxman A, Restrepo‐Jaramillo R, Thenappan T, Ravichandran A, Engel P, Bajwa A, Allen R, Feldman J, Argula R, Smith P, Rollins K, Deng C, Peterson L, Bell H, Tapson V, Nathan SD. Inhaled treprostinil in pulmonary hypertension due to interstitial lung disease. N Engl J Med 384: 325‐334, 2021.
 221.Westöö C, Norvik C, Peruzzi N, van der Have O, Lovric G, Jeremiasen I, Tran PK, Mokso R, de Jesus PV, Brunnström H, Bech M, Galambos C, Tran‐Lundmark K. Distinct types of plexiform lesions identified by synchrotron‐based phase‐contrast micro‐CT. Am J Physiol Lung Cell Mol Physiol 321: L17‐l28, 2021.
 222.Wilkins MR. Personalized medicine for pulmonary hypertension: The future management of pulmonary hypertension requires a new taxonomy. Clin Chest Med 42: 207‐216, 2021.
 223.Wilkinson M, Langhorne CA, Heath D, Barer GR, Howard P. A pathophysiological study of 10 cases of hypoxic cor pulmonale. Q J Med 66: 65‐85, 1988.
 224.Williams SM, Golden‐Mason L, Ferguson BS, Schuetze KB, Cavasin MA, Demos‐Davies K, Yeager ME, Stenmark KR, McKinsey TA. Class I HDACs regulate angiotensin II‐dependent cardiac fibrosis via fibroblasts and circulating fibrocytes. J Mol Cell Cardiol 67: 112‐125, 2014.
 225.Wohrley JD, Frid MG, Moiseeva EP, Orton EC, Belknap JK, Stenmark KR. Hypoxia selectively induces proliferation in a specific subpopulation of smooth muscle cells in the bovine neonatal pulmonary arterial media. J Clin Invest 96: 273‐281, 1995.
 226.Wright JL, Petty T, Thurlbeck WM. Analysis of the structure of the muscular pulmonary arteries in patients with pulmonary hypertension and COPD: National Institutes of Health nocturnal oxygen therapy trial. Lung 170: 109‐124, 1992.
 227.Yaginuma G, Mohri H, Takahashi T. Distribution of arterial lesions and collateral pathways in the pulmonary hypertension of congenital heart disease: A computer aided reconstruction study. Thorax 45: 586‐590, 1990.
 228.Yang H, Shelat AA, Guy RK, Gopinath VS, Ma T, Du K, Lukacs GL, Taddei A, Folli C, Pedemonte N, Galietta LJ, Verkman AS. Nanomolar affinity small molecule correctors of defective Delta F508‐CFTR chloride channel gating. J Biol Chem 278: 35079‐35085, 2003.
 229.Yeager ME, Halley GR, Golpon HA, Voelkel NF, Tuder RM. Microsatellite instability of endothelial cell growth and apoptosis genes within plexiform lesions in primary pulmonary hypertension. Circ Res 88: e8‐e11, 2001.
 230.Yeager ME, Voelkel NF, Tuder RM. Mutational analysis of endothelial cell TGF‐β receptor type II in plexiform lesions of patients with primary pulmonary hypertension. Circulation 100: I‐587, 1999.
 231.Yu YA, Malakhau Y, Yu CA, Phelan SJ, Cumming RI, Kan MJ, Mao L, Rajagopal S, Piantadosi CA, Gunn MD. Nonclassical monocytes sense hypoxia, regulate pulmonary vascular remodeling, and promote pulmonary hypertension. J Immunol 204: 1474‐1485, 2020.
 232.Yu YR, Mao L, Piantadosi CA, Gunn MD. CCR2 deficiency, dysregulation of Notch signaling, and spontaneous pulmonary arterial hypertension. Am J Respir Cell Mol Biol 48: 647‐654, 2013.
 233.Yuan K, Liu Y, Zhang Y, Nathan A, Tian W, Yu J, Sweatt AJ, Shamshou EA, Condon D, Chakraborty A, Agarwal S, Auer N, Zhang S, Wu JC, Zamanian RT, Nicolls MR, de Jesus Perez VA. Mural cell SDF1 signaling is associated with the pathogenesis of pulmonary arterial hypertension. Am J Respir Cell Mol Biol 62: 747‐759, 2020.
 234.Zaiman A, Fijalkowska I, Hassoun PM, Tuder RM. One hundred years of research in the pathogenesis of pulmonary hypertension. Am J Respir Cell Mol Biol 33: 425‐431, 2005.
 235.Zamanian RT, Badesch D, Chung L, Domsic RT, Medsger T, Pinckney A, Keyes‐Elstein L, D'Aveta C, Spychala M, White RJ, Hassoun PM, Torres F, Sweatt AJ, Molitor JA, Khanna D, Maecker H, Welch B, Goldmuntz E, Nicolls MR. Safety and efficacy of B‐cell depletion with rituximab for the treatment of systemic sclerosis‐associated pulmonary arterial hypertension: A multicenter, double‐blind, randomized, placebo‐controlled trial. Am J Respir Crit Care Med 204: 209‐221, 2021.
 236.Zhang H, Laux A, Stenmark KR, Hu CJ. Mechanisms contributing to the dysregulation of miRNA‐124 in pulmonary hypertension. Int J Mol Sci 22: 3852, 2021.
 237.Zhang H, Wang D, Li M, Plecita‐Hlavata L, D'Alessandro A, Tauber J, Riddle S, Kumar S, Flockton A, McKeon BA, Frid MG, Reisz JA, Caruso P, El Kasmi KC, Jezek P, Morrell NW, Hu CJ, Stenmark KR. Metabolic and proliferative state of vascular adventitial fibroblasts in pulmonary hypertension is regulated through a microRNA‐124/PTBP1 (polypyrimidine tract binding protein 1)/pyruvate kinase muscle axis. Circulation 136: 2468‐2485, 2017.
 238.Zhang Y, Talwar A, Tsang D, Bruchfeld A, Sadoughi A, Hu M, Omonuwa K, Cheng KF, Al‐Abed Y, Miller EJ. Macrophage migration inhibitory factor mediates hypoxia‐induced pulmonary hypertension. Mol Med 18: 215‐223, 2012.
 239.Zhao L, Chen CN, Hajji N, Oliver E, Cotroneo E, Wharton J, Wang D, Li M, McKinsey TA, Stenmark KR, Wilkins MR. Histone deacetylation inhibition in pulmonary hypertension: Therapeutic potential of valproic acid and suberoylanilide hydroxamic acid. Circulation 126: 455‐467, 2012.

Contact Editor

Submit a note to the editor about this article by filling in the form below.

* Required Field

Article Title: Tensions in Taxonomies: Current Understanding and Future Directions in the Pathobiologic Basis and Treatment of Group 1 and Group 3 Pulmonary Hypertension
 

How to Cite

Sue Gu, Khushboo Goel, Lindsay M. Forbes, Vitaly O. Kheyfets, Yen‐rei A. Yu, Rubin M. Tuder, Kurt R. Stenmark. Tensions in Taxonomies: Current Understanding and Future Directions in the Pathobiologic Basis and Treatment of Group 1 and Group 3 Pulmonary Hypertension. Compr Physiol 2023, 13: 4295-4319. doi: 10.1002/cphy.c220010